PBM
CMPS

Propel Bio Management’s Compass Pathways CMPS Stock Holding History

Propel Bio Management’s Portfolio CMPS Stock Details CMPS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.11M Sell
573,086
-168,963
-23% -$1.71M 4.24% 7
2026
Q1 		$4.12M Sell
742,049
-119,729
-14% -$805K 2.6% 11
2025
Q4 		$5.95M Buy
861,778
+351,778
+69% +$2.15M 5.08% 7
2025
Q3 		$2.92M Buy
+510,000
New +$2.29M 2.93% 11
2025
Q1 		– Sell
-25,209
Closed -$95.3K – 20
2024
Q4 		$95.3K Sell
25,209
-54,791
-68% -$278K 0.09% 19
2024
Q3 		$504K Buy
+80,000
New +$564K 0.29% 18

Other funds holding CMPS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $3.38B AUM 214.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
EHI
Eagle Health Investments Greenwich, Connecticut $603M AUM 111.06% 1-Year Est. Return

Propel Bio Management's CMPS Position: Q2 2026 in Review

Propel Bio Management reduced its Compass Pathways (CMPS) stake by 23% in Q2 2026, selling an estimated $1.71M and leaving 573,086 shares worth $8.11M. The position accounts for 4.24% of the portfolio, ranked #7.

Propel Bio Management first reported a position in CMPS in Q3 2024 and has held it in 6 quarters since. 223 funds tracked by Wall St. Rank hold CMPS as of Q2 2026.

  • Propel Bio Management held 573,086 shares of Compass Pathways worth $8.11M as of Q2 2026.
  • Propel Bio Management sold 168,963 Compass Pathways shares in Q2 2026, an estimated $1.71M.
  • Compass Pathways made up 4.24% of Propel Bio Management's portfolio in Q2 2026, its #7 holding.
  • Propel Bio Management first reported a position in Compass Pathways in Q3 2024 and has held it in 6 quarters since.
  • 223 funds tracked by Wall St. Rank held Compass Pathways as of Q2 2026.

Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.